Bliss Gvs Pharma Limited

BSE: 506197 NSE: BLISSGVS
Bliss Gvs Pharma Limited - pharma in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24230MH1984PLC034771 Incorporated 11 December 1984 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: BLISSGVS · BSE: 506197 Public Limited Company pharma
Data last updated
Market Cap
₹7,305 Cr
BLISSGVS · NSE
Share Price
₹704.70
+2.57% today
Revenue
₹927 Cr
FY 2025-26 · +12.1% YoY
EBITDA
₹162 Cr
Margin 17.4%
Net Profit
₹132 Cr
FY 2025-26 · +56.1% YoY
P/E (TTM)
54.0x
P/B 6.2x
ROE
12.0%
ROCE 17.0%
Debt / Equity
0.05
Interest cover 9.4x

About Bliss Gvs Pharma Limited

Data last updated: 26 September 2026

Bliss Gvs Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 11 December 1984, the company has been in operation for over 42 years.

Registered with ROC Mumbai under CIN L24230MH1984PLC034771. Listed on BSE: 506197 and NSE: BLISSGVS.

Capital: an authorised share capital of ₹15 Cr and a paid-up capital of ₹10.62 Cr. Formerly known as Bliss Gvs Phrma Limited (Cn) and Bliss Chemicals and Pharmaceuticals India Limited. It is led by directors including Shruti Vishal Rao and Vibha Gagan Sharma.

Last AGM: 31 July 2025. Financial statements filed for year ended 31 March 2025. Office: 102 Hyde Park Sakivihar Road Andheri (East)., Mumbai, Maharashtra, India – 400072.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹927.11 Cr, a growth of 14.5% compared to the previous year. The net worth stands at ₹1,192.9 Cr (up 13.57% YoY). Total assets are valued at ₹1,265.32 Cr (up 6.84% YoY).

The company has a workforce of approximately 926 employees as per the latest available data. Its group structure includes 1 subsidiary.

The company is associated with 1 brand - Bliss Gvs. As per MCA filings, the company has open charges of ₹161 Cr and satisfied charges of ₹401.25 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website blissgvs.com.

Company Details of Bliss Gvs Pharma Limited
CIN L24230MH1984PLC034771
Registration Number 034771
Incorporation Date 11 December 1984
ROC Mumbai
Listing Status Listed (BSE: 506197, NSE: BLISSGVS)
Company Status Active
Date of Last AGM 31 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Narsimha Shibroor Kamath Ceo Shruti Vishal Rao Whole-Time Director Vibha Gagan Sharma Whole-Time Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    blissgvs.com
  • Social Media
  • Registered Address
    102 Hyde Park Sakivihar Road Andheri (East)., Mumbai, Maharashtra, India – 400072
  • Industry
    Pharma, Drug Formulation & Development
Company report
Bliss Gvs Pharma Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Bliss Gvs Pharma Limited report

Financials, compliance, directors, charges, ownership and filings for Bliss Gvs Pharma Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited has undergone 3 name changes throughout its history. The company was previously known as Bliss Gvs Phrma Limited (Cn), Bliss Chemicals And Pharmaceuticals India Limited, and Bliss Gvs Phrma Limited (Cn). The current legal name is Bliss Gvs Pharma Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Bliss Gvs Pharma Limited Current
Bliss Gvs Phrma Limited (Cn) Previous
Bliss Chemicals And Pharmaceuticals India Limited Previous
Bliss Gvs Phrma Limited (Cn) Previous

CIN History of Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited has one previous CIN (Corporate Identification Number): U24230MH1984PTC034771. The current CIN is L24230MH1984PLC034771, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24230MH1984PLC034771 Current
U24230MH1984PTC034771 Previous

Associated Brands with Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited operates one associated brand: Bliss GVS. These brands represent Bliss Gvs Pharma Limited's diversified market presence and brand portfolio.

Brand Description Website
Bliss GVS
Pharmaceutical products including suppositories and pessaries are manufactured. blissgvs.com

Business Activity of Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Bliss Gvs Pharma Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited is audited by KALYANIWALLA & MISTRY LLP for the financial year 2024. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
KALYANIWALLA & MISTRY LLP Locked Locked Locked
Premium access

Complete auditor history for Bliss Gvs Pharma Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors and KMP of Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited currently reports 5 directors and 3 key managerial personnel. 16 former directors have served the organization.

Current Directors and KMP
Name Designation Appointment Date Tenure Status
Shruti Vishal Rao
Also directs: Gvsk Llp, Bliss Gvs Pharma Limited, Kremoint Pharma Private Limited
Whole-Time Director 27 Jul 2006 20 Years 1 Months Current
Vibha Gagan Sharma
Also directs: Gvsk Llp, Bliss Gvs Pharma Limited, Kremoint Pharma Private Limited and 1 more
Whole-Time Director 29 Jul 2008 18 Years 1 Months Current
Shilpa Bhatia
Also directs: Bliss Gvs Pharma Limited, Amj Land Holdings Limited, Aeroflex Industries Limited
Director 11 Feb 2020 6 Years 7 Months Current
Santosh Laxman Parab
Also directs: Bliss Gvs Pharma Limited
Director 24 May 2016 10 Years 4 Months Current
Aditi Himanshu Bhatt
Also directs: Bliss Gvs Pharma Limited
Company Secretary 09 Aug 2018 8 Years 1 Months Current
Narsimha Shibroor Kamath
Also directs: Gvsk Llp, Jayvin Developer Llp, Bliss Gvs Pharma Limited
Ceo 10 Oct 2025 0 Years 11 Months Current
Showing 6 of 8 current directors and KMP. View all directors and KMP

Financials of Bliss Gvs Pharma Limited FY 2025-26 filings available

Bliss Gvs Pharma Limited reported revenue of ₹927.11 Cr (up 14.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹927 Cr
+14.5% YoY
EBITDA
₹162 Cr
+27.5% YoY
Profit After Tax
₹132 Cr
+56.1% YoY
Net Worth
₹1,193 Cr
+13.6% YoY
Total Assets
₹1,265 Cr
+6.8% YoY
Total Debt
₹21.75 Cr
-75.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue927810770752747577689
Revenue growth+12.1%+5.3%+2.3%-9.7%+49.3%-18.8%-21.8%
EBITDA16212712111744.74107110
EBITDA margin+17.4%+15.7%+15.8%+15.6%+6.0%+18.5%+16.0%
Profit before tax19012611710654.16104129
Net profit13284.4995.8670.6435.4368.53106
Net profit margin+14.2%+10.4%+12.5%+9.4%+4.7%+11.9%+15.4%
EPS (₹)12.218.007.216.801.456.649.43
Balance sheet
Total assets1,2651,1841,1061,022957952879
Net worth1,1931,050967884819808736
Total debt21.7588.1099.84102109122126
Cash & bank167213216103178145103
Net working capital718707708558626649625
Cash flow
Cash from operations13910610334.3113563.9746.70
Cash from investing(38.18)(75.49)(83.34)(6.36)(103)(45.38)(40.09)
Cash from financing(89.21)(30.20)(20.89)(24.94)(23.73)(20.80)(6.30)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue286257218244207198210218
Revenue growth (YoY)+37.7%+29.8%+3.7%+12.3%+13.0%-0.1%+4.8%+2.7%
Other income9.6011.1918.468.4635.4512.0715.275.04
EBITDA76.4044.4432.2743.4841.3321.0929.7941.48
EBITDA margin+26.8%+17.3%+14.8%+17.8%+19.9%+10.7%+14.2%+19.1%
Depreciation9.948.678.358.268.208.047.556.98
Interest0.582.011.493.045.471.681.083.83
Profit before tax75.4844.9540.8940.6463.1123.4436.4335.71
Tax24.117.9516.1212.0418.746.7910.6210.01
Net profit51.3737.0024.7728.6044.3716.6525.8125.70
EPS (₹)4.653.282.142.544.041.462.272.29
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue730667605598636466442
Revenue growth+3.9%+6.7%+6.1%-3.6%+40.9%+9.4%+2.5%
EBITDA13291.5866.0990.1510991.46100
EBITDA margin+18.1%+13.7%+10.9%+15.1%+17.2%+19.7%+22.7%
Profit before tax13394.1770.2611612691.19122
Net profit98.1369.1176.1185.2290.5967.5391.81
Net profit margin+13.5%+10.4%+12.6%+14.2%+14.2%+14.5%+20.8%
EPS (₹)9.166.554.848.218.946.548.95
Balance sheet
Total assets1,1801,1311,0691,020942850778
Net worth1,1551,059988937851756683
Total debt13.2367.7277.5080.5789.9191.8493.09
Cash & bank11117116984.6114912086.62
Net working capital662676691614662588572
Cash flow
Cash from operations12397.2182.1743.8111466.9763.22
Cash from investing(51.30)(77.97)(65.84)(12.97)(92.28)(61.62)(60.14)
Cash from financing(75.37)(26.56)(20.76)(26.05)(12.62)(11.67)(5.83)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue222212165190163156180183
Revenue growth (YoY)+35.7%+35.6%-8.3%+4.2%+9.7%-4.8%+11.3%+6.6%
Other income8.769.6610.2313.5910.599.3611.668.35
Total expenses170167140160131142154157
EBITDA51.8744.1524.3430.2732.7613.7325.7325.38
EBITDA margin+23.4%+20.9%+14.8%+15.9%+20.1%+8.8%+14.3%+13.9%
Depreciation9.037.847.807.697.687.436.966.39
Interest0.391.811.482.715.111.300.673.45
Profit before tax51.2144.1625.2933.4630.5614.3629.7623.89
Tax12.5911.746.688.669.512.918.726.84

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 26 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue286257218244207198210218
Revenue growth (YoY)+37.7%+29.8%+3.7%+12.3%+13.0%-0.1%+4.8%+2.7%
Other income9.6011.1918.468.4635.4512.0715.275.04
EBITDA76.4044.4432.2743.4841.3321.0929.7941.48
EBITDA margin+26.8%+17.3%+14.8%+17.8%+19.9%+10.7%+14.2%+19.1%
Depreciation9.948.678.358.268.208.047.556.98
Interest0.582.011.493.045.471.681.083.83
Profit before tax75.4844.9540.8940.6463.1123.4436.4335.71
Tax24.117.9516.1212.0418.746.7910.6210.01
Net profit51.3737.0024.7728.6044.3716.6525.8125.70
EPS (₹)4.653.282.142.544.041.462.272.29
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue927810770752747577689
Revenue growth+12.1%+5.3%+2.3%-9.7%+49.3%-18.8%-21.8%
Other income73.5336.4928.7417.7931.4920.2239.19
Total expenses766683649634703471579
Employee cost13611295.5886.1776.1568.0953.69
EBITDA16212712111744.74107110
EBITDA margin+17.4%+15.7%+15.8%+15.6%+6.0%+18.5%+16.0%
Depreciation33.4829.4226.3818.6717.3317.2312.59
Interest12.018.126.9110.364.745.517.57
Profit before tax19012611710654.16104129
Tax54.8635.3935.2929.3431.0430.1533.72
Net profit13284.4995.8670.6435.4368.53106
Net profit margin+14.2%+10.4%+12.5%+9.4%+4.7%+11.9%+15.4%
EPS (₹)12.218.007.216.801.456.649.43
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5810.5410.4710.4210.3710.3110.31
Reserves & surplus1,1821,040957873808798725
Shareholders' funds (net worth)1,1931,050967884819808736
Minority interest38.8641.4735.7933.5327.7619.6614.76
Secured loans2.9370.9762.5671.3668.3197.64104
Unsecured loans18.8217.1337.2830.5441.0824.2622.50
Total debt21.7588.1099.84102109122126
Total liabilities1,2651,1841,1061,022957952879
Assets
Gross block608532468459344286277
Net block459406370379281234242
Capital work in progress6.0520.717.832.8022.152.390.00
Investments4.974.384.177.802.390.010.02
Inventories15112611810312498.9376.92
Sundry debtors517439404385393464548
Cash & bank balances167213216103178145103
Loans & advances11045.9971.9010182.6457.9144.37
Total current assets945824810692777765773
Total current liabilities227117102135150116147
Net working capital718707708558626649625
Total assets1,2651,1841,1061,022957952879
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash23.8223.5925.0121.9913.1315.3415.04
Net cash from operating activities13910610334.3113563.9746.70
Net cash from investing activities(38.18)(75.49)(83.34)(6.36)(103)(45.38)(40.09)
Net cash from financing activities(89.21)(30.20)(20.89)(24.94)(23.73)(20.80)(6.30)
Net change in cash11.320.23(1.42)3.028.85(2.21)0.30
Closing cash167213216103178145103
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%+5.1%+2.5%+0.6%+29.5%-16.3%-23.3%
EBITDA growth+27.5%+4.3%+3.5%+162.2%-58.1%-3.0%-30.3%
PBT growth+50.9%+7.5%+10.2%+95.9%-48.0%-19.3%-29.1%
Net income growth+56.1%-11.9%+35.7%+99.4%-48.3%-35.5%-15.2%
Revenue CAGR (3Y)+7.3%+2.7%+10.1%+2.9%-6.0%-10.9%-4.8%
EBITDA CAGR (3Y)+11.3%+41.5%+4.4%+2.2%-34.3%-13.2%-18.5%
Profitability & leverage
Net income margin+14.5%+11.2%+10.6%+10.2%+3.1%+12.8%+13.8%
Return on capital employed+17.0%+12.1%+14.8%+12.1%+14.2%+12.2%+16.9%
Return on net worth+12.0%+9.0%+11.0%+9.0%+5.4%+9.6%+13.8%
Debt / equity0.050.090.110.120.140.160.17
Long-term debt / equity0.020.040.050.040.040.050.05
Interest cover9.388.357.2710.5017.296.167.78
Efficiency & per share
Fixed asset turnover1.631.621.661.872.372.053.08
Inventory turnover6.716.636.956.626.716.568.94
Debtors turnover1.941.921.951.931.751.141.37
EPS (₹)12.218.007.216.801.456.649.43
Dividend per share (₹)0.500.500.500.500.500.500.50
Book value per share (₹)112.7699.6892.3884.8778.9778.3671.32
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue222212165190163156180183
Revenue growth (YoY)+35.7%+35.6%-8.3%+4.2%+9.7%-4.8%+11.3%+6.6%
Other income8.769.6610.2313.5910.599.3611.668.35
Total expenses170167140160131142154157
EBITDA51.8744.1524.3430.2732.7613.7325.7325.38
EBITDA margin+23.4%+20.9%+14.8%+15.9%+20.1%+8.8%+14.3%+13.9%
Depreciation9.037.847.807.697.687.436.966.39
Interest0.391.811.482.715.111.300.673.45
Profit before tax51.2144.1625.2933.4630.5614.3629.7623.89
Tax12.5911.746.688.669.512.918.726.84
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue730667605598636466442
Revenue growth+3.9%+6.7%+6.1%-3.6%+40.9%+9.4%+2.5%
Other income43.7236.2233.5050.7735.3717.6837.00
Total expenses598576539508527374342
Employee cost12299.4282.5972.5465.0658.6144.02
EBITDA13291.5866.0990.1510991.46100
EBITDA margin+18.1%+13.7%+10.9%+15.1%+17.2%+19.7%+22.7%
Depreciation31.0227.0523.5215.1713.8513.768.83
Interest11.116.585.8110.064.324.196.62
Profit before tax13394.1770.2611612691.19122
Tax36.5925.2019.6230.2133.7323.6829.37
Net profit98.1369.1176.1185.2290.5967.5391.81
Net profit margin+13.5%+10.4%+12.6%+14.2%+14.2%+14.5%+20.8%
EPS (₹)9.166.554.848.218.946.548.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital10.5810.5410.4710.4210.3710.3110.31
Reserves & surplus1,1451,048978927841745673
Shareholders' funds (net worth)1,1551,059988937851756683
Secured loans0.0023.1045.8365.7164.6967.8771.49
Unsecured loans13.2344.6231.6714.8625.2223.9721.60
Total debt13.2367.7277.5080.5789.9191.8493.09
Total liabilities1,1801,1311,0691,020942850778
Assets
Gross block555478414386270212203
Net block420369331326225175180
Capital work in progress4.4020.587.832.8022.152.390.00
Investments18.6918.6918.6918.2618.2618.3018.31
Inventories11181.9489.4574.1590.1183.6860.57
Sundry debtors457429400399409349405
Cash & bank balances11117116984.6114912086.62
Loans & advances14883.9911417214312590.55
Total current assets826766772730792677643
Total current liabilities16489.4281.7211613088.5970.94
Net working capital662676691614662588572
Total assets1,1801,1311,0691,020942850778
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.8514.1718.6013.824.6711.0013.75
Net cash from operating activities12397.2182.1743.8111466.9763.22
Net cash from investing activities(51.30)(77.97)(65.84)(12.97)(92.28)(61.62)(60.14)
Net cash from financing activities(75.37)(26.56)(20.76)(26.05)(12.62)(11.67)(5.83)
Net change in cash(3.52)(7.32)(4.43)4.799.14(6.33)(2.75)
Closing cash11117116984.6114912086.62
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.4%+10.2%+1.2%-6.0%+36.7%+5.3%+3.6%
EBITDA growth+44.0%+38.6%-26.7%-17.5%+19.4%-8.7%+7.6%
PBT growth+41.7%+34.0%-39.3%-8.5%+38.6%-25.1%+1.4%
Net income growth+42.0%-9.2%-10.7%-5.9%+34.2%-26.5%+21.0%
Revenue CAGR (3Y)+6.8%+1.6%+9.2%+10.6%+14.3%+16.0%+8.3%
EBITDA CAGR (3Y)+13.5%-5.7%-10.3%-3.5%+5.5%+1.1%-0.3%
Profitability & leverage
Net income margin+13.3%+10.3%+8.4%+14.3%+14.6%+14.5%+20.9%
Return on capital employed+12.5%+9.2%+11.2%+12.8%+14.6%+11.7%+17.6%
Return on net worth+8.8%+6.7%+7.9%+9.6%+11.5%+9.4%+14.4%
Debt / equity0.040.070.080.100.110.130.13
Long-term debt / equity0.020.040.050.040.040.050.05
Interest cover11.0210.2013.6513.424.535.397.25
Efficiency & per share
Fixed asset turnover1.411.501.511.822.642.252.97
Inventory turnover7.577.797.407.297.326.457.66
Debtors turnover1.651.611.521.481.681.241.18
EPS (₹)9.166.554.848.218.946.548.95
Dividend per share (₹)0.100.500.500.500.500.500.50
Book value per share (₹)109.20100.4794.4189.9682.1273.2666.21
Want more history and ratios?
You're viewing the latest exchange-filed financials for Bliss Gvs Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Bliss Gvs Pharma Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 35.00%, foreign institutional investors hold 8.10%, domestic institutional investors hold 9.40%, retail and other public shareholders hold 47.50% of Bliss Gvs Pharma Limited.

Promoters: 35.00%DII (Domestic Institutional): 9.40%FII (Foreign Institutional): 8.10%Retail & Others: 47.50%
Jun 2026
QUARTER
35.00% Promoters
9.40% DII (Domestic Institutional)
8.10% FII (Foreign Institutional)
47.50% Retail & Others
Promoter holding - history
Now 35.00% · Jun 2026High 35.40% · Sep 2025Low 35.00% · Jun 2026
34%34.8%35.5%36.3%37%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 35.40%Dec 2025: 35.40%Mar 2026: 35.40%Jun 2026: 35.00%35.40%35.00%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters35.00%35.40%35.40%35.40%
Public65.00%64.60%64.60%64.60%

Group Structure of Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited has 1 subsidiary company. This group structure data is as of FY 2023. The corporate group structure reflects Bliss Gvs Pharma Limited's business expansion strategy and organizational complexity.

1
Subsidiary companies
Key Subsidiaries
Company Name CIN Shares Held
Kremoint Pharma Pvt. Ltd. U24230MH1992PTC066737 -

Showing major subsidiaries. Total: 1.

Charges & Borrowings of Bliss Gvs Pharma Limited

Open charges
₹161 Cr
Satisfied charges
₹401.25 Cr
Breakdown by lending institutions
Others₹160.00 Cr
Hdfc Bank Limited₹1.00 Cr
Latest charge details
DateLenderAmountStatus
02 Sep 2023 Others ₹75 Cr Open
21 Nov 2020 Hdfc Bank Limited ₹1 Cr Open
07 Oct 2006 Others ₹85 Cr Open
16 Dec 2023 Others ₹35 Cr Satisfied
17 Sep 2021 Others ₹65 Cr Satisfied

Total charge records: 23 View all charges

Employees and EPFO Compliance at Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited has a workforce of 926 employees as of Mar 31, 2025.

Employee count
926
Active EPFO establishments
1
Employee growth
13.9%
Premium access

Employee and EPFO history for Bliss Gvs Pharma Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Bliss Gvs Pharma Limited

Premium access

GST registrations and filing compliance for Bliss Gvs Pharma Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Bliss Gvs Pharma Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Bliss Gvs Pharma Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Bliss Gvs Pharma Limited

Premium access

MSME payment history for Bliss Gvs Pharma Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Bliss Gvs Pharma Limited

Premium access

Corporate group structure for Bliss Gvs Pharma Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Bliss Gvs Pharma Limited

Premium access

MCA filings and documents for Bliss Gvs Pharma Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Bliss Gvs Pharma Limited

Charges
30 Mar 2026
A charge registered on 17 Sep 2021 via Charge ID 100488249 with Others was fully satisfied on 30 Mar 2026.
Charges
09 Jan 2026
A charge registered on 16 Dec 2023 via Charge ID 100843177 with Others was fully satisfied on 09 Jan 2026.
Directors
10 Oct 2025
Narsimha Shibroor Kamath was appointed as a CEO on 10 Oct 2025 & has been associated with this company since 11 months 17 days.
Activity
31 Jul 2025
Bliss Gvs Pharma Limited last Annual general meeting of members was held on 31 Jul 2025 as per latest MCA records.
Activity
31 Mar 2025
Bliss Gvs Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
30 Jan 2025
A charge with Others of Rs. 75.00 Cr registered on 02 Sep 2023 with Charge ID 100791236 was modified on 30 Jan 2025.

Recent News on Bliss Gvs Pharma Limited

Bliss GVS Pharma arm clears USFDA inspection of Ambernath facility
09 Oct 2019 · Business Medical Dialogues

Frequently Asked Questions about Bliss Gvs Pharma Limited

Bliss Gvs Pharma Limited is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 11 December 1984 (42+ years old) and is registered under CIN L24230MH1984PLC034771. Listed on BSE: 506197 and NSE: BLISSGVS. The company has 926 employees.

Bliss Gvs Pharma Limited reported revenue of ₹927.11 Cr for FY 2025-26 (up 14.5% YoY) based on consolidated financials.

The current directors and KMP of Bliss Gvs Pharma Limited are:

The primary industry of Bliss Gvs Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Bliss Gvs Pharma Limited is listed on both BSE (code: 506197) and NSE (symbol: BLISSGVS).

Bliss Gvs Pharma Limited can be reached at the registered office: 102 Hyde Park Sakivihar Road Andheri East, Mumbai, Maharashtra, India – 400072, or through the website blissgvs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available